INVESTING IN THE FUTURE OF HEALTH

- Perspective from our Leaders → 2
- Battling COVID → 5
- Accelerating New Treatments, Delivering Impact → 9
- Advancing Global Health → 14
- Recognizing Excellence → 18

ACKNOWLEDGING DONORS → 22
BOARD OF DIRECTORS → 36
FINANCIAL HIGHLIGHTS → 37
At the FNIH we often talk about identifying inflection points: those challenges and moments where a collaborative investment of human and financial resources can drive significant, lifesaving biomedical research.

In these pages, you’ll learn how our early focus on one such inflection point — the establishment of a unique research collaboration to respond to the COVID-19 pandemic — yielded results in 2021, delivering definitive data on potential treatments to address SARS-CoV-2. These treatments were prioritized and then tested using “master protocol” clinical trials designed and executed through the FNIH-managed Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership.
As the pandemic continues to evolve, so does the ACTIV partnership, tackling new critical questions. ACTIV’s Tracking Resistance and Coronavirus Evolution (TRACE) Working Group, for example, is taking a leading role in monitoring how current vaccines and therapeutics work on emerging viral variants.

2021 also marked an important inflection point for the FNIH as an institution. In September, FNIH President and Executive Director Dr. Maria Freire stepped down after nine years of remarkable leadership. We’re deeply grateful for her significant contributions to the FNIH and to human health. In December, we also bid farewell to NIH Director Dr. Francis Collins, a tremendous scientific leader and longtime champion of FNIH’s efforts to accelerate biomedical research and innovation by building strong alliances among governments, industry, and foundations.

These leadership changes had special resonance because they occurred during our 25th anniversary year. Anniversaries serve as their own inflection points, offering the opportunity to both celebrate past achievements and plan for the future. For the FNIH, 2021 was a time to intensify our pursuit of new discoveries and initiatives that promise to make life better for patients across many diseases and around the world.

For example, this year our long-standing Biomarkers Consortium partnership identified new tools that may pave the way toward improved treatments — and a better patient experience — for those who suffer from Alzheimer’s disease and serious liver disease. We extended our support for the Comprehensive Cellular Vaccine Immune Monitoring Consortium (CCVIMC), which provides fresh insight into the decades-long challenge of creating a vaccine for HIV. And our newly launched Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium (AMP® BGTC) Program is speeding the delivery of promising new therapies to patients with rare diseases that currently lack effective treatments.
Welcome Julie Gerberding!

The FNIH is delighted to welcome Dr. Julie L. Gerberding as our new CEO effective May 16, 2022.

As the first woman to lead the Centers for Disease Control, Dr. Gerberding managed responses to dozens of public health emergencies, including avian influenza and SARS-CoV-1. She later joined Merck as President of Vaccines, oversaw Global Public Policy and Strategic Communications for the company, and most recently served as Chief Patient Officer and Executive Vice President, Population Health & Sustainability. A leading voice for patient safety and empowerment, Dr. Gerberding has created programs addressing antimicrobial resistance, infection prevention, and medical error reduction in healthcare settings. At the FNIH, she will assume a critical role in guiding the continued growth of the FNIH and expansion of its unique public health mission.

ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.
When desperately ill COVID-19 patients first began knocking at the doors of U.S. hospitals, healthcare workers frantically sought to develop effective treatments for the disease. Across the world, individual scientists as well as research institutions launched hundreds of studies to test various potential remedies. Unfortunately, many of these studies were too small or inadequately designed to yield conclusive results. Meanwhile, a number of unsubstantiated reports of “effective” treatments flooded the media, which did little to relieve the “infodemic” overwhelming the healthcare workers trying to help these patients.
A nationally coordinated, focused plan for addressing the pandemic was clearly needed — and Dr. Francis Collins called on the FNIH to create a solution. The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership that resulted was formed in record time in April 2020. Over the following 10 months, ACTIV reviewed more than 800 potential COVID-19 treatments and launched 11 robustly designed “master protocol” clinical trials, each capable of testing multiple drugs in a relevant patient population and funded through NIH by the U.S. government's Operation Warp Speed initiative. Since its inception in April 2020, the ACTIV trial networks have tested over 30 therapies for effectiveness against COVID-19.

Of these promising leads, several have already reported results, with a majority of the trials due to read out by the fall of 2022. During 2021, data from the ACTIV trials contributed to Emergency Use Authorizations for three treatments, including the monoclonal antibody therapies from Brii Biosciences, Eli Lilly, and AstraZeneca, and led to an important change in clinical practice for the use of anticoagulation therapies in hospitalized COVID-19 patients. Importantly, ACTIV's prioritization efforts meant that valuable resources — money, laboratory space, healthcare workers' time, and patients' hopes — were focused on therapies likely to succeed as COVID-19 treatments.

ACTIV, which includes eight U.S. government agencies, four nonprofit organizations, and 20 industry partners, stands out as perhaps the most remarkable collaboration to arise from the COVID-19 response. Its formation relied on the FNIH's proven partnership model — engage people and organizations with diverse knowledge, unique capabilities, and distinct viewpoints, and create an environment based on objective science where trust and the exchange of new ideas can thrive — while achieving its goals with unprecedented scale and speed. It's a blueprint that the FNIH will continue to follow to tackle a host of difficult biomedical challenges stemming from the current pandemic and many future challenges to human health.


“Having had the experience of working with the FNIH in the programs we call AMP, the Accelerating Medicines Partnership Program, I knew that creating this kind of partnership would be a really good way to build trust and capabilities in approaching COVID. We worked hard together through this incredibly challenging time in history, and amazing things have happened.”

Dr. Francis Collins
Former Director of NIH
In early 2020, scientists at NIH and around the world had quickly sequenced the new SARS-CoV-2 virus and began creating effective tools for stopping it. But then came the Beta variant. Gamma, Delta, and, most recently, Omicron variants followed. Each successive wave of the coronavirus caused death and disruption across the globe and threatened to diminish the effectiveness of newly available COVID-19 vaccines and therapies.

The urgency of tracking and studying these variants became painfully clear. While a variety of platforms were and continue to be used by different countries to sequence and share virus data, the FNIH and NIH recognized early on that a coordinated, global perspective is essential to understand the evolution of the virus and the impact of variants on therapeutics and vaccines.

In January 2021, the FNIH convened government agencies, academics, and private partners to establish the Tracking Resistance and Coronavirus Evolution (TRACE) initiative. Through genomic surveillance, data sharing, and assessments of treatment responses to new virus strains, TRACE standardizes and consolidates data from genetic databases worldwide to monitor and test COVID-19 variants. TRACE also assesses vaccine and therapeutic resistance and evaluates the impact of genetic variation on viral biology and on the clinical approaches for preventing and treating illness.
Looking Ahead

In 2021, the FNIH supported a series of high-level consultations with experts from global health law, financing, biomedical science, prominent international organizations, and others to inform the international community on the potential for a global pandemic treaty. The FNIH also hosted a public forum among thought leaders from the World Health Organization, NIH, FDA, Pfizer, and the Chicago Community Trust on how the COVID-19 response is shaping the future of science.

These efforts were made possible by The Judy and Peter Blum Kovler Foundation and by the FNIH Pandemic Response Fund, which supports NIH and FNIH efforts to accelerate research on COVID-19 vaccines and treatments, end the threat from COVID-19, and prepare the United States to defend against future pandemics.
Rare diseases are defined in the U.S. as those that affect fewer than 200,000 people — with some afflicting as few as 10 individuals in the world. But collectively these diseases are responsible for widespread harm. Some 25 to 30 million Americans, as well as their families and communities, suffer from the approximately 7,000 rare diseases known today, with few effective treatments.
One type of treatment has emerged that offers hope: gene therapy, a process that replaces defective genes that cause disease with functional ones. While gene therapies have been successfully used to treat common genetic diseases, they can also be tailored (or “bespoke”) for much smaller populations. Developing these therapies, however, is complex and often expensive, and small patient populations make it challenging to get an adequate return on investment in the development process.

The Bespoke Gene Therapy Consortium (BGTC) promises to change the playing field for gene therapy development. Launched in late 2021 by the FNIH, NIH, and the FDA, the BGTC aims to generate a standardized “plug-and-play” that makes it easier to develop new gene therapies. Rather than create a custom therapy for each disease from scratch, developers could soon be able to use and reuse this common template to produce therapies more quickly and at lower cost.

The BGTC is the latest initiative to emerge from the FNIH’s highly successful Accelerating Medicines Partnership (AMP) Program. Building on the AMP collaboration model, the BGTC program brings together 30 public and private sector organizations, including many rare disease patient groups, to support a series of research projects and clinical trials intended to refine and standardize trial design, regulatory evaluation, and manufacturing processes, enabling the field to deliver more viable treatments for rare diseases to more patients.

Building on Success

The FNIH launched the first three Accelerating Medicines Partnership programs together with NIH in 2014. Focused on Alzheimer’s disease, type 2 diabetes, and rheumatoid arthritis and lupus, they generated genomic and molecular data and analytical approaches that have substantially advanced our understanding of drug targets in these diseases.

These three partnerships have proved so successful that each has not only produced follow-on efforts that considerably expand their original research agendas, but they have also inspired completely new AMP programs in Parkinson’s disease, schizophrenia, and gene therapies.
Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE)

THE PROMISE:
Non-alcoholic steatohepatitis (NASH) is a serious liver disease estimated to affect between 9 and 15 million people in the U.S. The disease often remains undiagnosed in its early stages and can require a liver transplant or cause liver cancer — and ultimately death. Currently, diagnosing early-stage NASH requires a liver biopsy: a painful, invasive, and expensive process. In November 2021, the FNIH Biomarkers Consortium released the initial results from its NIMBLE project, which seeks to assess the suitability of several non-invasive, blood-based biomarkers for use in clinical trials of treatments for NASH. Several of these biomarkers did a better job of identifying patients at risk of developing NASH or progressing to cirrhosis than current standard tests and compared favorably with the diagnostic performance of liver biopsy, the current reference standard.

THE IMPACT:
Although further confirmatory study may be required, the new biomarkers examined by NIMBLE could potentially replace the need for patients who have or who may be at risk for NASH to undergo biopsies. If approved by the FDA, tests using these new markers could enable early and accurate diagnosis of at-risk patients, improving the quality of care, accelerating drug development, and reducing the burden imposed by current clinical care practices.
ACCELERATING NEW TREATMENTS, DELIVERING IMPACT

Partnership for Accelerating Cancer Therapies (PACT)

THE PROMISE:
Immunotherapies — treatments that stimulate the body's own immune system to fight cancer — have proven to be an effective and promising therapeutic option for certain cancers in recent years. Yet these immune treatments do not work for all patients and we lack a precise understanding of why. Developing standardized biomarker tests to understand how immunotherapies work in some patients, and thus to predict patient responses to treatment, is urgently needed for these therapies to benefit the maximum number of people.

PACT, a five-year public-private research collaboration launched in 2019 by NIH, the FNIH, FDA, and 12 pharmaceutical companies as part of the Cancer Moonshot, integrates the expertise of researchers at four top cancer research centers — Dana-Farber Cancer Institute, Stanford University, MD Anderson Cancer Center, and Mount Sinai Medical Center — to develop these assays and harmonize them for use across the cancer field.

THE IMPACT:
To date, PACT researchers have analyzed over 5000 samples from 12 clinical trials in different cancers and used the resulting data to validate existing assays across all four laboratories. Six existing assays commonly used in assessing immunotherapies and combination therapies across 15 different cancers have been harmonized to date. The resulting standards have been published in four major journal articles to make sure these tests can be performed uniformly in laboratories across the U.S. As data anticipated from an additional 35 trials becomes available, PACT researchers will be able to use it to help develop new biomarkers to help physicians select the most optimal immunotherapy treatments for their patients.
ACCELERATING NEW TREATMENTS, DELIVERING IMPACT

Mucosal Healing for Ulcerative Colitis

THE PROMISE:
In April 2021, the FNIH Biomarkers Consortium launched its Mucosal Healing in Ulcerative Colitis (UC) Project to improve diagnosis and treatment of a debilitating inflammatory bowel disease that affects more than three million people worldwide. This three-year initiative aims to generate best practices and consensus standards for assessing disease activity at the tissue-level in UC clinical trials. The program also hopes to develop cutting-edge methodologies to measure mucosal healing — the body’s ability to restore intestinal lining damaged by UC, and an important outcome in clinical trials — more accurately in the future.

THE IMPACT:
Creating a more precise measure with which to judge the outcome of clinical trials promises to meaningfully accelerate the development of new therapies for patients with UC. The ability to use a common protocol and automate the evaluation of mucosal inflammation and healing will enable these measurements to be applied more consistently, precisely, and rapidly and may reduce the number of biopsies needed. The goal is to advance physicians’ ability to help guide appropriate treatment to reduce or even prevent relapses and complications, improving the patient experience.
In the midst of an already-stalled global struggle against malaria, COVID-19-related disruptions to health care systems prompted a dangerous resurgence of this deadly disease in 2020. Recognizing the urgent need for new strategies, in May 2021 the World Health Organization (WHO) — with support from the FNIH’s GeneConvene Global Collaborative — published an updated guidance framework to inform research and development of genetically modified mosquitoes.
Modifying the genes of malaria-carrying mosquitoes can reduce their ability to reproduce, so that there are fewer to spread the disease, or decrease the mosquitoes’ ability to transmit the malaria parasite. If proven safe, effective, and affordable, these technologies could offer a game-changing addition to the existing arsenal of interventions against malaria. But there are many important questions for decision makers to address when evaluating whether and how to move forward with research and implementation.

The FNIH-led GeneConvene initiative works to ensure that all stakeholders — including researchers, policymakers, regulators, and communities affected by malaria — are equipped with the right tools to make informed, responsible decisions about these technologies. The new WHO guidance is a significant milestone in this effort. It provides answers to some of the toughest questions in the field, including:

• How can the potential effectiveness and risks of genetically modified mosquitoes on reducing disease be evaluated?

• What are the key ethical considerations?

• Which regulatory frameworks will oversee decisions about research?

Like many other FNIH collaborations, GeneConvene centers on a critical inflection point where advances in biomedical research depend on bringing diverse groups together to pursue a common goal. With malaria causing more than 600,000 deaths worldwide in 2020 alone, there is an urgent need to evaluate the promise of genetically modified mosquitoes both quickly and responsibly.
Hundreds of participants around the world joined a 2021 series of virtual discussions cohosted by GeneConvene and McMaster University in Ontario, Canada, to explore critical ethical questions related to gene drive. Topics included the ethical principles that should govern gene drive research, and justice and equity considerations for applying gene drive at the local community level.

The Gene Drive Research Forum (GDRF) organized by GeneConvene developed these panels, as well as a companion series — co-hosted by GeneConvene and the Genetic Biocontrol of Invasive Rodents (GBIRd) Partnership — that focused on best practices for engaging stakeholders to explore gene drive technologies together.
In July 2021, the Gates Foundation renewed for another five years the remarkable work of the Comprehensive Cellular Vaccine Immune Monitoring Consortium (CCVIMC).

Focused on supporting the development of an effective vaccine for HIV, the virus that causes AIDS, the CCVIMC convenes leading scientists to provide standardized measurements from clinical and pre-clinical studies of the disease and share data to optimize vaccine platforms being developed through the Collaboration for AIDS Vaccine Discovery.

Globally 1.5 million people are infected with HIV annually. Over the next five years the CCVIMC will continue to build on research enabling new approaches to HIV vaccines to be studied. The end goal is development of a safe and broadly effective vaccine that will prevent HIV infection.
Recognizing Excellence

THE LURIE PRIZE IN BIOMEDICAL SCIENCES

The Lurie Prize in Biomedical Sciences is an annual award given to promising younger investigators who have achieved groundbreaking advances in biomedical science. In 2021, the FNIH honored Xiaowei Zhuang, Ph.D., for her revolutionary work on developing super-resolution microscopy and genome-scale imaging that revealed new spatial and functional organizations of molecules and cells.

Dr. Zhuang’s innovative work with microscopy has enabled researchers to visualize with high resolution the positioning of and interactions between molecules in a cell, as well as the spatial organization of distinct types of cells in tissues. Her discoveries have made a significant impact.
across the field of biology, with seminal applications to cell biology.

Dr. Zhuang is a professor at Harvard University, a Howard Hughes Medical Institute investigator, and co-founder of the life sciences company Vizgen.

The Prize is made possible by a generous gift from noted philanthropist and FNIH Honorary Board Member Ann Lurie.

TRAILBLAZER PRIZE FOR CLINICIAN-SCIENTISTS

The Trailblazer Prize for Clinician-Scientists was established in 2018 to highlight the essential role of early career clinician-scientists whose research has led or has the potential to lead to innovations in patient care.

In 2021, Piro Lito, M.D., Ph.D., Associate Member and Attending Physician at Memorial Sloan Kettering Cancer Center, was awarded the prize for catalyzing breakthroughs in the understanding of oncprotein signaling and the development of novel therapeutic approaches for cancer.

Working at the interface of basic research and clinical practice, Dr. Lito studies how mutated proteins drive tumor growth. He is particularly interested in a protein called KRAS, which is commonly mutated in lung, colorectal, and pancreatic cancers. Dr. Lito has uncovered how mutant KRAS transitions between its active and inactive states in cancer cells and, by exposing vulnerable events during this transition, he has made key contributions to the development of novel therapeutic approaches for cancer.

Funding for the Trailblazer Prize is provided by the Gallin Fund at the FNIH.

CHARLES A. SANDERS, M.D., PARTNERSHIP AWARD

Each year, the FNIH bestows the Charles A. Sanders, M.D., Partnership Award to recognize people or organizations that have made particularly significant contributions to the Foundation’s efforts to build, implement, and nurture public-private partnerships in support of the mission of the NIH.

In 2021, the FNIH presented the Partnership Award to Janssen Research & Development, LLC, and to the eight Co-Chairs of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Groups.
Janssen Research & Development, LLC, the Pharmaceutical Companies of Johnson & Johnson, has been an exemplary partner and leader across many FNIH programs, including ACTIV, several Accelerating Medicines Partnerships®, the Biomarkers Consortium, the Partnership for Accelerating Cancer Therapies (PACT), and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). The many Janssen scientists who have participated in these partnerships have consistently promoted a highly collegial, collaborative approach to problem-solving with an emphasis on teamwork and transparent communication that enables open, precompetitive science.

In support of finding therapeutics and vaccines to combat COVID-19, the ACTIV Working Group Co-Chairs spent countless hours collaborating with the FNIH and NIH to design strategies for combating the COVID-19 pandemic and execute them with unprecedented speed. They participated in hundreds of meetings, reporting regularly to the ACTIV Leadership Team, and devoted valuable time and effort to identify opportunities for and help resolve challenges to the partnership. Their all-out efforts were essential to enabling ACTIV to navigate the rapidly changing nature of the threats to global human health posed by SARS-CoV-2.

Funding for the Charles A. Sanders, M.D., Partnership Award is provided by the Charles A. Sanders Legacy Fund at the FNIH.
Janssen R&D, LLC

Alex Gorsky
Executive Chairman,
Johnson & Johnson

The Co-Chairs of the ACTIV Working Groups

Christine M. Colvis, Ph.D.
Director of Drug Development Partnership Programs, National Center for Advancing Translational Sciences (NCATS) at NIH

Elizabeth Desrosiers, M.S., P.M.P.
Executive Director of Clinical Sciences and Study Management at Merck & Co., Inc.

Eric Hughes, M.D., Ph.D.
Global Head of Clinical Development and Analytics at Novartis

Kathrin Jansen, Ph.D.
Senior Vice President and Head of Vaccine Research and Development at Pfizer

Michael Kurilla, M.D., Ph.D.
Director, Division of Clinical Innovation, National Center for Advancing Translational Sciences (NCATS) at NIH

Douglas Lowy, M.D.
Principal Deputy Director, National Cancer Institute (NCI) at NIH

Sarah Read, M.D.
Deputy Director, Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID) at NIH

John Young, Ph.D.
Global Head of Infectious Diseases and Vice President at Roche Pharma Research and Early Development
THANK YOU TO OUR 2021 DONORS

We acknowledge and thank each of our donors — the many generous individuals, not-for-profits, foundations, and corporations listed here. Your unrestricted gifts provide important flexibility to meet urgent needs. Restricted gifts serve specific areas of programming — often through funds and endowments that also provide for the future. Our Statutory Report to Congress reports private-sector contributions by donor name, exact gift amount, and purpose of each gift.

Gifts made by our donors enable the FNIH to fulfill its mission of advancing human health. The ongoing generosity of both individuals and institutions allows us to establish and grow innovative research, training, and education initiatives that truly “move the dial” on biomedical research and ultimately benefit patients and their families. During 2021, three separate gifts illustrate how donations to the FNIH support present advances in research and offer hope for the future.

THANK YOU to the Corliss Foundation. A new donor in 2021, the Corliss Foundation’s gift funds rare kidney cancer research, specifically hereditary leiomyomatosis and renal cell cancer (HLRCC). Funding supports the laboratory of Dr. Marston Linehan, the leading researcher globally in making inroads in cures for kidney cancer, at the National Cancer Institute.

THANK YOU to the Estate of James T. Wendel. His 2021 bequest supports research in neuromuscular and neurogenetic disorders in children. Funding to the National Institute of Neurological Disorders and Stroke benefits the work of Dr. Carsten Bönnemann, whose lab is identifying the genetic and cellular mechanisms of these diseases in hopes of developing molecular-based treatment.

THANK YOU to the Judy and Peter Blum Kovler Foundation. In 2021, the Foundation made the first-ever philanthropic gift to the National Institute on Minority Health and Health Disparities. The gift funds a research fellowship for Dr. Gargya Malla to support NIH’s Community Engagement Alliance Against COVID-19 Disparities.
“NIH’s Community Engagement Alliance Against COVID-19 Disparities works closely with the communities hit hardest by COVID-19. As donors, we are glad to support this initiative by funding a fellow who can provide critical coordination in communities of color, creating positive change in health disparities.”

Judy and Peter Kovler

$15,000,000+

Bill & Melinda Gates Foundation [20] ImmunityBio

$10,000,000 – $14,999,999

Amgen Inc. [19] Novartis Pharmaceuticals Corporation [22]

$5,000,000 – $9,999,999

Eli Lilly and Company [22]

$2,500,000 – $4,999,999

Bristol Myers Squibb [23] ROCHE [15]
### ACKNOWLEDGING OUR DONORS

#### $1,000,000 – $2,499,999

- Alzheimer's Association ® [17]
- Boehringer Ingelheim Pharmaceuticals, Inc. [4]
- The Michael J. Fox Foundation for Parkinson's Research [5]
- Gilead Sciences, Inc. [6]
- McKnight Brain Research Foundation
- Merck Sharp & Dohme Corp. [24]
- Otsuka Pharmaceutical Development & Commercialization, Inc. [2]
- Regeneron Pharmaceuticals, Inc. [9]
- Spark Therapeutics
- Thermo Fisher Scientific Inc. [2]
- Ultragenyx Pharmaceutical [2]
- Estate of James T. Wendel ≪

#### $500,000 – $999,999

- Alzheimer's Drug Discovery Foundation [9]
- AstraZeneca Pharmaceuticals [20]
- Canon Medical Systems USA, Inc. ≫
- CureDuchenne
- Echosens SA ≫
- Eisai Inc. [2]
- Jazz Pharmaceuticals [2]
- Lupus Research Alliance
- National Organization for Rare Disorders (NORD)
- National Psoriasis Foundation
- Nordic Bioscience A/S [3]*
- REGENXBIO Inc.
- Schizophrenia & Psychosis Action Alliance
- Siemens ≫
- Sjögren's Foundation [3]
- Sysmex Inostics
- Taysha Gene Therapies

#### $250,000 – $499,999

- Alkermes, Inc. [3]
- Arthritis Foundation [12]
- GE Healthcare ≫
- Genfit ≫
- OWL Metabolomics ≫
- Dr. and Mrs. Joram Piatigorsky [2]
- Sage Therapeutics [3]
- Verily [2]*
ACKNOWLEDGING OUR DONORS

$100,000 – $249,999

Alector, Inc. [5]
Alliance for Regenerative Medicine
The ALS Association
American Psychiatric Association Foundation [2]
American Society of Gene & Cell Therapy
Amgen Foundation
Bayer AG [9]
BrightFocus Foundation [3]
Buffy and William Cafritz Family Foundation [18]
Corliss Foundation
Driven To Cure, Inc. [6]
EMD Serono, Inc. [6]
Estate of Brenda Marie Geist ¥
Jayne Koskinas Ted Giovanis Foundation for Health and Policy
Ann Lurie [10]
National Alliance on Mental Illness [3]
The National Institute for Innovation in Manufacturing Biopharmaceutical (NIIMBL)
One Mind [2]
PerkinElmer Inc. [2]*
Rett Syndrome Research Trust
The Edmond J. Safra Foundation [4]∞
Nina K. Solarz [2]A

$50,000 – $99,999

American Association for Dental, Oral, and Craniofacial Research [9]
The Association for Frontotemporal Degeneration [3]
The Nicholls Biondi Foundation
Deeda Blair [6]*
The Bluefield Project to Cure Frontotemporal Dementia [3]
Dr. and Mrs. Marijn Dekkers [4]*
James H. Donovan [10]*
Renée Fleming Foundation [2]
Estate of Jean Lough Heagy ¥
Mr. and Mrs. Paul M. Montrone [24]∞
Novalis LifeSciences LLC
The Pew Charitable Trusts [8]
Pharmaceutical Research and Manufacturers of America [17]
Philips *
Rainwater Charitable Foundation
Mrs. Lily Safra [4]∞
Fred A. and Donna Seigel [19]*
SuperSonic Imagine *
Dr. and Mrs. Robert H. Wurtz
ACKNOWLEDGING OUR DONORS

$25,000 – $49,999

Adaptive Biotechnologies Corporation [6]
Astellas Pharma Inc. [2]
Bio-Rad Digital Biology Group
Booz Allen Hamilton Inc.
Colgate-Palmolive Company [4]
FUJIFILM Toyama Chemical Co., Ltd. [6]
GenMab US, Inc. [4]
Hologic, Inc.
Invicro, LLC [3]
Judy and Peter Blum Kovler Foundation [8]*
In memory of Buffy Cafritz
Life Molecular Imaging [11]

$10,000 – $24,999

Anonymous (2) “
Abbott “^*
The Jeffrey A. Abrams and Rosalyn L. Abrams Charitable Trust
ADx NeuroSciences [3]
AMRA Medical [4]
Araclon Biotech, S.L. [6]
Braidwell Management Company LP
C2N Diagnostics [4]
Cerevel Therapeutics
CHDI Foundation
Clario [14]
Cognition Therapeutics, Inc. [3]
William W. Crouse

The Lupus Foundation of America
Michael Jefferson Meagher [2]
Annette L. Nazareth and Roger W. Ferguson, Jr. [3]
Bob and Sally Newcomb [11]
Mary Kathryn Norman-Navab
Gilbert S. Omenn, M.D., Ph.D. and Martha A. Darling [14]*
Renvy Graves Pittman
Radiomics
Jane M. Sayer, Ph.D.
Paul Stoffels, M.D. and Katelijne Bruurs [5]*

Cytokinetics, Inc. [2]
The Geaton & JoAnn DeCesaris Family Foundation, Inc.
In memory of Betty DeCesaris
Robert L. and Janice Diamond [3]
In honor of John I. Gallin
Harvey J. Alter, M.D. and Diane Dowling, Ph.D.
John and Margot Ernst
EUROIMMUN AG
Friends of Cancer Research [12]*
Christopher and Elise Gladstone
In memory of Buffy Cafritz
Goulston & Storrs PC [3]
Cathy Graham
Estate of Jack Gramlich ¥
ACKNOWLEDGING OUR DONORS

Carol-Ann Harris [9]
Ikena Oncology [2]
Dr. and Mrs. Thomas R. Insel [5]*
Ionis Pharmaceuticals, Inc. [2]
IXICO Technologies Limited [3]
Patricia S. Kohlen [3]*
Laboratory Corporation of America [2]
Julie Bell Lindsay [7]
In memory of T. Douglas Lindsay
H. Lundbeck A/S [6]
Steve and Sherry Mayer [9]*
Meridian Bioscience
Morgan Stanley & Co. Incorporated [3]
MyoKardia
Myovant Sciences
Amir Nashat - Polaris Partners
Neurimmune AG
NEWMARK

Olink Proteomics [5]
Steven and Jann Paul [2]*
Posey-Glickert Foundation [4]
Quanterix
Dame Jillian Sackler [19]*
Charles A. Sanders, M.D. and Ann E. Sanders [25]*
In memory of Buffy Cafritz
Seagen, Inc.
Sengenics Corporation [8]
Gerald R. Sigal and Ellen V. Sigal, Ph.D. [12]*
Solomon H. Snyder, M.D. [6]*
Russell W. Steenberg and Patricia Colbert [9]
Todd Wagner Foundation *
The Richard H. Yearick Foundation [2]*
Elias A. Zerhouni, M.D. and Nadia Zerhouni, M.D. [9]*

$5,000 – $9,999

Anonymous (3) *
AccessCircles Inc
American Society for Reproductive Medicine
Association for Molecular Pathology [4]
John Bertschy [3]*
Ralph H. and Karen K. Craft [5]*
Elsevier, Inc.
Frederick National Laboratory for Cancer Research [9]

Francesca Fleischer
In memory of Thomas K. Grundman
Drs. Maria & Ernesto Freire [10]*
In memory of Buffy Cafritz
Theodore N. Giovanis, M.B.A. [3]*
Randy K. Glantz [4]
The Multiple Myeloma Research Foundation [2]
National Rongxiang Xu Foundation
PathAI, Inc. [2]
ACKNOWLEDGING OUR DONORS

Elizabeth Peabody  
Radiological Society of North America [13]

Sunny Raspet [9]∞

Matthew Scher and Barbara Lazio [9]  
In memory of Barbara L. Lazio, Carol Scher and Jane Paull Scher

Steven L. and Karin Siegel ∞

Andrew and Elyse Steinhaus [6]

Vizgen

The Harry and Jeanette Weinberg Foundation, Inc.

Steve and Chris Wilsey [13]  
In honor of Dr. Louis Staudt

Richard and Nadine Woldenberg
In honor of Robert A. Seder

$2,500 – $4,999

Ariannie Fund ∞

Ronald and Barbara Berke [12]∞

Zachary T. Bloomgarden, Ph.D. and Kathy F. Bloomgarden, Ph.D. ∞

Ambassador Nancy G. Brinker ∞
In memory of Buffy Cafritz

Facebook Donors [5]∞

James M. Felser, M.D. [12]

Henry L. Hecht [5]  
In honor of Stuart H. Yuspa

Teresa and Kevin Klock [7]∞
In honor of Maria C. Freire, David Wholley, Julie Wolf-Rodda, Robert Balthaser, Michael Santos, Don Hill, Janelle Lewis, Tania Kamphaus, Catherine Master, Vanessa Perlman, Katherine Thompson, and Robert Eiss, and in memory of Fred and Helen Balding

Lisa Kuzel [2]∞
In memory of Leslie Happ

Ann Lemmon ∞

Kunal Patel [2]∞
In memory of Kanta Patel

Dr. Sapna Patel ∞

Lenore R. Salzman [6]

Barbara Santos [2]  
In memory of Carlos Santos

Society for Immunotherapy of Cancer [5]

Tony and Meredith Stern ∞
In memory of Andrew L. Stern

Technomics Research ∞

University of Pennsylvania ∞
In honor of Anthony Fauci

Sara Lou Whildin [9]∞

David Wholley [10]∞

Wolk Family Fund [4]∞

$1,000 – $2,499

Anonymous (4) “
Aegis Sciences Corporation
Douglas Albright
In memory of Janet Albright
America’s Charities [7]∞
Jeffrey D. and Ann Anderson [5]∞
Apple Inc. [5]∞
John and Sandra Atkins [5]∞
Dr. Nadarajah Balasubramanian [5]∞
Robert Balthaser and Ricardo C. Araneda, Ph.D. [15]∞
Lori Bettinger “
In memory of Charles Francer
Jon H. Beusen and Denise D. Beusen, Ph.D. [8]∞
In tribute to various friends
Charles J. and Connie Bocklet
In memory of Connie Bocklet
David J. Bouman
In memory of Leah R. Fickes
Marc and Debbie Breslaxw [2]∞
Donald Burrows [2]
In honor of David Schrump
Dan Balliet and Jan Carlson [13]∞
Cerf-Dunbar Fund [13]∞
Gina D. Chalmers [3]∞
Jeffrey Chow [4]
Stewart A. Daniels, M.D. “
Paul J. Davis, M.D. [2]∞
Drug Safety Navigator “
Terence F. Eagleton
In honor of Catherine M. Blair
Alicia Emerson [5]∞
In memory of Scott Emerson
Margaret J. Erhart “
Ronald G. Evens, M.D. [2]∞
Susan E. Finley [6]∞
Ruth Friedman “
James and Karen Gavic [12]∞
Keith Gendler [6]∞
Ginkgo Bioworks
Google, Inc. [7]∞
Gene and Esther Gorman [7]
Margaret Grieve [9]
Dr. Batsheva Halberstam “
In honor of Dr. Peter Williamson, Dr. Seher Anjum, and their team
Dr. and Mrs. Paul L. Herrling [8]∞
Hewlett Packard Enterprise [4]∞
Drs. Susan and Peter Honig [3]∞
Horizon Therapeutics plc
Hubble Charitable Fund [2]∞
Jamari Foundation “
Laura Jansen [3]∞
Richard Jonas and Katherine Vernot-Jonas [14]∞
Kenneth and Rhoda Herman Foundation “
Douglas M. and Lynn C. Klock [40]∞
Dr. Louis Y. Korman “
Ronald L. Krall, M.D. and Susan J. Krall [10]∞
ACKNOWLEDGING OUR DONORS

Jeremy Krasner [2]
Philip and Nancy N. Lee [2]
Howard H. and Jacqueline K. Levine [2]
Edison T. Liu, M.D., Ph.D. and Margaret B. Liu [4]
John Madden, Jr. [3]
Paul D. Manca, J.D. [3]
In memory of William Manca and Ralph Johnson
John and Stacy Martin [2]
Ari and Abbey Meltzer [7]
In memory of Dy'trea Langon
Raymond Michael [5]
Caroline R. Milbank
In honor of Catherine M. Blair
William Morley and Caroline Trahan [5]
In honor of Kyle Trahan
Mr. Mehdi Nafissi and Dr. Ann F. Welton [14]
The Nederlander Organization
In memory of Buffy Cafritz
Paul and Cindy Obermeyer [2]
Omega World Travel Inc. [7]
Sheela Pai Cole [2]
Matt and Robyn Nichols Painter [3]
Sarah Palamara [4]
Farhan Panthaki [5]
Edmund and Megan Pantuliano
Brian Park [4]
Joseph G. Perpich, M.D., J.D. and Cathy J. Sulzberger [3]
In honor of Maria C. Freire
Jeffrey Peterson
Mr. and Mrs. Stephen Peth [13]
Rebecca Phinney [2]
Eric F. Polhamus 6
John S. Rhim, M.D.
Robert A. and Marjorie Rosenberg [9]
Rosemary Rosso
In memory of Mary Rogers S. Brunet
Ruder & Finn, Inc.
Dr. Pirmin Schmid
In memory of the research fellow
Elizabeth K. Schodek
Edward A. Seidel, M.D. [3]
Norman E. Sharpless, M.D.and Julie Sharpless, M.D. [9]
Richard I. and Anastasia Smith [9]
Joann Spence
In memory of Leah R. Fickes
Truist [11]
Christopher A. and Elizabeth Thoma [8]
In memory of Oberon Christopher Thoma
David Van Hemel
Jon and Kristin Vaver [14]
Daniel M. Voorhees
In memory of Leah R. Fickes
Roger Weisman [4]
Stewart K. Wilson [10]
In memory of Christina Wilson, Blaise Ribet, Beulah Wilson, and Allan Wilson
Julie and Howard Wolf-Rodda [15]
Martin Wolk
Daniel Zhao [5]
Shuxun Zhou
ACKNOWLEDGING OUR DONORS

$500 – $999

Anonymous (2)
Dr. James S. Alexander
Amazon Smile Foundation
Dr. and Mrs. James E. Balow, M.D. [7]
{
In honor of Jamie and Kim Balow, Jeff and Jill Balow, and Dennis and Caroline Capoccia
}
Barbara Basden
Sheila Bassett [2]
James K. and Deborah M. Bieging [5]
Margaret Blair
Paula L. and William C. Bradley [3]
Keith F. and Alison Burrows [1]
Lan Chang, M.D.
City of Hope Division of Nursing Research
Rochelle S. Cohen [2]
{
In memory of Ruth P. Rosen
}
Dr. Francis Collins and Diane Baker
B.A. Dass [3]
Ronald Early [3]
Dr. Roland D. Eavey and Dr. M.S. Desmond [3]
{
In honor of Anthony S. Fauci
}
Drs. Howard J. Eisen and Judith E. Wolf [2]
Richard W. Erbe, M.D.
{
In memory of Philip Leder
}
Ergonomic Group Inc
{
In memory of Jean M. Buscemi
}
Carol Ertel
Daniel H. Ertel
F5 Networks [3]
Faye Fager [3]
{
In memory of Gregory B. Fager
}
Jeffrey and Marilyn Finn [6]
Joseph N. and Michie Flanz [5]
{
In memory of Adam J. Berry
}
Laren Friedman [8]
Dr. Rona G. Giffard, M.D.
Barry H. Ginsberg, M.D., Ph.D. [3]
Randall and Holly Griffin [5]
Stacy F. Harrison [2]
Chris and Laura C. Hazzard [13]
{
In memory of Richard Curtin
}
Stephen and Teri Herbst [4]
William E. and Louise A. Hess
Susan C. Horowitz [7]
{
In memory of Arthur G. Horowitz
}
John L. and Mary Emma C. Hoye [7]
Luanne Hudson
International Monetary Fund [2]
Stephanie L. James, Ph.D. [11]
{
In memory of Michael Gottlieb
}
James F. and Gudrun Jeffrey [6]
Joseph Gawler’s Sons, LLC
Michael M. Kaback, M.D.
{
In honor of H. Ronald Kaback
}
Melissa Kuskin [2]
Lafayette 89 [3]
{
In memory of Ewen Raballand
}
Arnold Lakind
ACKNOWLEDGING OUR DONORS

John Larabee [4]∞
Aleah Laxton [4]∞
In honor of Bo Cooper
Janelle Lewis [2]∞
Cheryl Liechty ∞
In memory of Michael Gottlieb
Nancy R. Madden ∞
In memory of David L. Madden
Mrs. Marlene Malek [3]∞
In memory of Buffy Cafritz
John F. Malmros and Rosemary F. Contin [2]∞
Cathleen Martin [9]∞
Catherine Master [3]∞
In memory of Betsy Parker
Charles McCormick ∞
Judi McCormick ∞
In memory of Buffy Cafritz
The Honorable and Mrs. Matthew McHugh [9]
Laurence McMillan [3]∞
Deborah Nevins
In memory of Vivianne M. Chaumont
Mariann O’Brien ∞
The Pittsburgh Foundation [4]
Premier Inc [2]∞
Jan and William Price ∞
Helen R. Quill, Ph.D. [3]∞
Kathleen M. Reardon ∞
In honor of Irini Sereti
The Relias Family [7]
Research!America [2]
Glen Richards [4]∞
Joel and Barbara Richmon ∞
Jennifer Rosenbluth-Stoll and Peter Stoll [4]∞
John Salvino ∞
In honor of Al and Carole Salvino
Michael Santos, Ph.D. [2]∞
In honor of the life of Michael Gottlieb, on behalf of the FNIH Science Department
Benjamin A. Schwartz [2]∞
In memory of Robert McDermott
Dr. John N. Sheagren ∞
Robert B. and Tammy Renee Sher [2]∞
Daniel R. Shively ∞
Lorene Steinberg [1]
In memory of Steven Steinberg
Drs. Thomas A. Steitz and Joan A. Steitz [4]∞
Jamie Stern ∞
In memory of Andrew L. Stern
StudiGo LLC ∞
In honor of Francis S. Collins
Suncor Energy [4]∞
In honor of Bo Cooper
Samuel O. Thier, M.D. and Paula Thier [16]
William, Zani and Aycen Tolentino [13]∞
Kevin and Caroline Vaughn
In memory of Connie Bocklet
Andrew Veale ∞
Paula J. Warrick, Ph.D. [3]∞
Susan Wechsler ∞
In memory of Buffy Cafritz
Theodore and Katherine Wells [6]∞
Wiley Rein LLP [6]∞
Lucas and Katrina Yun-Nikolac [9]∞
Dr. Stuart H. Yuspa and Eleanor H. Yuspa
ACKNOWLEDGING OUR DONORS

$250 – $499

Jonathan Abney [2]
Stephen and Sharon Alpert [5]
Ruwan Alwis [2]
In honor of Anthony S. Fauci
Bank of America Matching Gifts Program [2]^
Albert M. Bernath, Jr., M.D.
The Bigger Family Foundation
In memory of Kelly M. Harty
Will and Berta Blades [6]
Jeffrey Blumenstein [2]
Kenny and Peri Boersema
In honor of Kenny and Peri Boersema wedding guests
Michelle Borrus
Manson K. Brown [3]
John S. Buchignani, M.D. [2]
Louis Maximilian Buja, M.D. [3]
Alex P. and Drew E. Burrows [2]
Raymond and Bonnie Carlson [13]
Kandis Cooke
In memory of Connie Bocklet
Martin J. Corso, M.D. [9]
Larry Day [7]
Jeff J. Doenges [2]
Mark C. Donaldson [2]
William and Renee Enright [4]
Elinore Eschmann
In memory of Connie Bocklet
Arlene L. Feit [9]
In memory of David M. Feit
Fitch Group ^
We Chen Foo [2]
Thomas Gasparini [5]
Margaret Gavin [6]
Martin Gellert, Ph.D. [6]
Spencer Griffin [3]
David and Marijean Hahn
In memory of Jean M. Buscemi
Eric J. and Susan Hatch [5]
Gregory and Sally Henderson [5]
Donald Hill and Carolyn Ross [5]
Willard Hillegeist [7]
In honor of Julie Bell Lindsay and in memory of Doug Lindsay
Andrew Huff
In memory of Keith Murphy
David R. Inman
Robert S. and Raissa H. Johnson [3]
Michael and Nancy Kelly
In honor of Todd Grams
Mark and Cathy Knepper [8]
Andrew Kraus
In memory of Connie Bocklet
Rich Krauzlis
In honor of Robert H. Wurtz
Linde
Dr. and Mrs. Lewis A. Lipsitz [5]
Berit Lund
In memory of Leah R. Fickes
Dongxin Luo [2]
Leonard and Karen Madoff
ACKNOWLEDGING OUR DONORS

William and Stephanie Marra [3]
Anne Alexander Marshall, Ph.D. and Davis Marshall [17]
Randall McEntire
Cheryl L. Melencio [3]
Microsoft Corporation [6]^
Judith Miller [4]
Morton L. Moss, M.D. [5]
John M. Mulhern
Gretchen Naylor
Northrop Grumman Corporation [9]^
Jacqueline Ratner
Kimberly Rhodes
In honor of Elise Van Leer
Michael J. Richman [3]
Lori A. Rolnick [4]
In memory of Adam Berry
Sidney Rosenzweig [8]
Joseph Scardapane
In memory of Jean M. Buscemi
Darren Schneider [7]
Dr. and Mrs. George Schneider [12]
Lloyd Shorter and Jolly Clarkson-Shorter [2]
In honor of Kenneth Olivier

James Simpson [2]
In memory of John Christopher Scott
Dr. and Mrs. David J. Steinberg
Rainer F. Storb, M.D.
Suresh and Feroza Subramani [4]
Michael Sullivan [6]
Anthony Tassone [10]
Chris Themak
Tischfield Family Charitable Gift Fund
In memory of Peter J. Stambrook
Meredith Upton
In honor of Maria C. Freire
Harold E. Varmus, M.D. [2]
Marjorie Weiner
Ingrid Wiley [13]
Dyann Wirth
In memory of Michael Gottlieb
Jay Yarington
Joel Yesley [14]
Vincenzo Zitarosa
In memory of Jean M. Buscemi
ACKNOWLEDGING OUR DONORS

LEGACY SOCIETY

Anonymous (6)
The Jeffrey A. Abrams and Rosalyn L. Abrams Charitable Trust
Jon H. Beusen and Denise D. Beusen, Ph.D.
Mrs. William McCormick Blair, Jr.
Paula L. and William C. Bradley
Estate of David P. Brown
William and Buffy Cafritz
Estate of Michael T. Davis
Estate of Linda Founds
Estate of Brenda Marie Geist
Keith Gendler
Estate of Jonathan D. Gest
Craig R. Gochanour, Ph.D.
Estate of Jack Gramlich
Estate of Linford M. Hallman
Carol-Ann Harris
Estate of Charles Harris
Haverchack Family Trust
Estate of Jean Lough Heagy
Estate of Sallie Rosen Kaplan
Patricia S. and Ken Kohlen
Julie Bell Lindsay
Dorothy O. Newcomb Trust
Dr. and Mrs. Abner L. Notkins
Patricia Nowosacki
Estate of Patrick M. O’Connor, Ph.D.
Dean O’Neill Irrevocable Living Trust
Estate of Jennifer R. Price
Estate of Frances H. Saupe
Jane M. Sayer, Ph.D.
Estate of Gary Snoke
Nina K. Solarz
Estate of James T. Wendel
Estate of Eugene Woolf and Dismas S. Blanco

TO LEARN MORE ABOUT WAYS TO GIVE, PLEASE VISIT THE FOLLOWING LINKS:

PARTNERS SOCIETY: FOR DONORS WHO GIVE $500 OR MORE UNRESTRICTED DURING THE YEAR. LEARN MORE AT FNHIH.ORG/PARTNERSSOCIETY.

LEGACY SOCIETY: FOR QUESTIONS REGARDING BEQUESTS OR ESTATE PLANNING VISIT FNHIH.ORG/PLANNEDGIVING.

TRIBUTE AND MEMORIAL GIVING: LEARN MORE ABOUT GIFTS TO HONOR SOMEONE SPECIAL AT FNHIH.ORG/TRIBUTEGIVING.

FUNDS AND ENDOWMENTS:
CONTRIBUTE TO OR ESTABLISH A FUND OR ENDOWMENT THAT ADVANCES RESEARCH IN A PARTICULAR AREA OF INTEREST BY SEARCHING FNHIH PROGRAMS AT FNHIH.ORG/PROGRAMS.

RESEARCH PROGRAMS:
FIND A SPECIFIC RESEARCH PROGRAM TO DONATE TO AT FNHIH.ORG/PROGRAMFUNDRAISING.

Please call 301.402.4976 or email advancement@fnih.org with questions.
2021 BOARD OF DIRECTORS

OFFICERS

Steven M. Paul, M.D.  
Chairman

Maria C. Freire, Ph.D.  
President and Executive Director

Solomon H. Snyder, M.D.  
Vice Chairman

Steven C. Mayer  
Treasurer

Mrs. William McCormick Blair, Jr.  
Secretary

ELECTED DIRECTORS

Kathy Bloomgarden, Ph.D.  
Buffy Cafritz  
Marijn Dekkers, Ph.D.  
James H. Donovan  
Paul L. Herrling, Ph.D.  
Thomas R. Insel, M.D.  
Judy Lansing Kovler, Ph.D.  
Ronald L. Krall, M.D.  
Freda C. Lewis-Hall, M.D., DFAPA, MFPM  
Julie Bell Lindsay  
Edison T. Liu, M.D., Ph.D.

Joel S. Marcus  
Gilbert S. Omenn, M.D., Ph.D.  
Jillian Sackler, D.B.E.  
Lily Safra  
Charles A. Sanders, M.D.  
Fred Seigel  
Ellen V. Sigal, Ph.D.  
Russell W. Steenberg  
Paul Stoffels, M.D.  
Elias Zerhouni, M.D.

EX OFFICIO DIRECTORS

Francis S. Collins, M.D., Ph.D.  
Janet Woodcock, M.D.

DIRECTORS EMERITI

Paul Berg, Ph.D.  
Sherry Lansing  
Paul M. Montrone, Ph.D.  
The Honorable John Edward Porter

HONORARY DIRECTORS

Ann Lurie  
Samuel O. Thier, M.D.  
Patrick C. Walsh, M.D.
## Financial Highlights

### Revenue and Support

<table>
<thead>
<tr>
<th>Source</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$100,066,760</td>
<td>$96,981,262</td>
</tr>
<tr>
<td>Grants</td>
<td>43,744</td>
<td>40,694</td>
</tr>
<tr>
<td>Administrative Revenue</td>
<td>50,000</td>
<td>-</td>
</tr>
<tr>
<td>Transfers from NIH</td>
<td>1,250,000</td>
<td>1,250,000</td>
</tr>
<tr>
<td>Investment Income</td>
<td>1,882,441</td>
<td>2,789,697</td>
</tr>
<tr>
<td>In-kind Contributions</td>
<td>3,936,832</td>
<td>600,486</td>
</tr>
<tr>
<td>Donated Services</td>
<td>16,900</td>
<td>49,500</td>
</tr>
<tr>
<td>Fundraising Event</td>
<td>352,300</td>
<td>330,000</td>
</tr>
<tr>
<td>Other Revenue</td>
<td>913,617</td>
<td>350,943</td>
</tr>
<tr>
<td><strong>Total revenue and support</strong></td>
<td>$108,512,594</td>
<td>$102,392,582</td>
</tr>
</tbody>
</table>
### EXPENSES AND CHANGES IN NET ASSETS

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Program services</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fellowships and Training Programs</td>
<td>$852,431</td>
<td>$541,462</td>
</tr>
<tr>
<td>Memorials, Awards, and Events</td>
<td>457,912</td>
<td>521,016</td>
</tr>
<tr>
<td>Capital Projects</td>
<td>53,512</td>
<td>43,887</td>
</tr>
<tr>
<td>Research Programs</td>
<td>50,719,285</td>
<td>51,546,218</td>
</tr>
<tr>
<td><strong>Total program services</strong></td>
<td>$52,083,140</td>
<td>$52,652,583</td>
</tr>
<tr>
<td><strong>Supporting services</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management and General</td>
<td>$6,310,346</td>
<td>$6,609,054</td>
</tr>
<tr>
<td>Fundraising</td>
<td>374,002</td>
<td>437,019</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td>$6,684,348</td>
<td>$7,046,073</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td>$58,767,488</td>
<td>$59,698,656</td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td>$49,745,106</td>
<td>$42,693,926</td>
</tr>
<tr>
<td><strong>Net assets beginning of year</strong></td>
<td>161,204,216</td>
<td>118,510,290</td>
</tr>
<tr>
<td><strong>Net assets at end of year</strong></td>
<td>$210,949,322</td>
<td>$161,204,216</td>
</tr>
</tbody>
</table>

### 2021 EXPENSES

- **86.3%**  
  Research Partnerships
- **2.3%**   
  Education and Events
- **11.4%**  
  Management and Fundraising

---

(*FNIH 2021 ANNUAL REPORT*)
The Foundation for the National Institutes of Health (FNIH) creates and manages alliances with public and private institutions in support of the mission of the NIH. The FNIH works with its partners to accelerate biomedical research and strategies against diseases and health concerns in the United States and across the globe. Established by Congress in 1990, the FNIH is a not-for-profit 501(c)(3) charitable organization.

For additional information about the FNIH, please visit fnih.org

To view our timeline of programs and initiatives, visit fnihtimeline.fnih.org